Navigation Links
Inoperable Colon Cancer Responds to New Treatment
Date:6/16/2009

Individuals from 26 U.S. states and four other countries have been among the first to use NeoPlas Innovation's new protocol.

Nashville, Tenn. (Vocus) June 16, 2009 -- With an extensive, inoperable colon cancer and few options available, a Tennessee patient is seeing his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and four other countries have been among the first to use NeoPlas Innovation's new protocol. The Tennessee patient's early results mirror their successes in battling colon cancer and other very aggressive malignancies.

The most recent colon cancer patient is a man in his late fifties who had an extensive cancer of the lower colon diagnosed in early 2008. Initially his doctors recommended surgical resection in an operation that would have removed all the organs of his lower abdomen and pelvis; however, it was determined that he would be unlikely to survive the procedure. Chemotherapy was tried, but was ineffective. He visited NeoPlas Innovation's Nashville clinic in the spring of 2009 and began the new outpatient treatment.

Two months later, CT scans have shown that the cancer has regressed dramatically. The patient's symptoms are resolving in step with the response, with improvements in appetite and digestion and the regaining of lost weight. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are results from one patient, so no conclusions can be drawn. But this is consistent with the favorable responses we're seeing in the great majority of our patients, including those with colon cancer." The protocol is offered for qualifying patients with colon cancer, renal (kidney) cancer, pancreatic cancer, melanoma, mesothelioma and certain sarcomas. It can be considered for other patients on a case-by-case basis.

The new treatment is an off-label combination of two existing medicines: lovastatin, typically used as a cholesterol lowering agent, and interferon. According to Dr. Cantrell, "The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising." NeoPlas Innovation patients often have seen the arrest of their cancers' growth and spread in as few as eight weeks of treatment. In many cases, such as this one, patients have experienced active regression of tumors.

The medicines used have the advantage of being safe and well tolerated. Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

NeoPlas Innovation's web site, www.neoplas.org, provides complete information and an interactive screening tool for patients who are considering this treatment. The clinic can be reached at (615) 371-8100.

For an interview with Dr. Cantrell, call 615-371-8100.

###

Read the full story at http://www.prweb.com/releases/Colon_Cancer/Cancer_Treatment/prweb2544534.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. New Treatment Option at The Sarah Cannon Cancer Center Provides Hope for Inoperable Tumors
2. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
3. St. Jude study offers new hope for children with kidney tumors deemed inoperable
4. For Some, Virtual Colonoscopy May Be Just As Good
5. VA Faces Questions Over Tainted Colonoscopies
6. For Some, Virtual Colonography May Be Just As Good
7. Racial Clusters Seem to Affect Access to Colon Care
8. Colonoscopy Risks Increase With Age and Illness
9. Weight May Affect Colonoscopy Success
10. Deep Sleep May Improve Colonoscopy Results
11. Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Inoperable Colon Cancer Responds to New Treatment
(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
Breaking Medicine Technology: